Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ, Janssen EM.

Cancer Res. 2011 Oct 15;71(20):6428-37. doi: 10.1158/0008-5472.CAN-11-2154. Epub 2011 Jul 25.

PMID:
21788345
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, Adema GJ.

PLoS One. 2009 Dec 18;4(12):e8368. doi: 10.1371/journal.pone.0008368.

PMID:
20020049
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P.

J Clin Invest. 2008 Mar;118(3):1165-75. doi: 10.1172/JCI33583.

PMID:
18259609
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.

Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M.

J Clin Invest. 2012 Feb 1;122(2):575-85. doi: 10.1172/JCI61034. Epub 2012 Jan 17.

PMID:
22251703
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.

Kool M, Geurtsvankessel C, Muskens F, Madeira FB, van Nimwegen M, Kuipers H, Thielemans K, Hoogsteden HC, Hammad H, Lambrecht BN.

J Leukoc Biol. 2011 Dec;90(6):1177-90. doi: 10.1189/jlb.0610342. Epub 2011 Sep 20.

PMID:
21934071
[PubMed - indexed for MEDLINE]
Free Article
6.

Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.

Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ.

Cancer Res. 2014 Mar 15;74(6):1670-81. doi: 10.1158/0008-5472.CAN-13-0777. Epub 2014 Jan 30.

PMID:
24480625
[PubMed - indexed for MEDLINE]
7.

TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.

Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM.

J Immunol. 2011 Feb 15;186(4):2422-9. doi: 10.4049/jimmunol.1002845. Epub 2011 Jan 17.

PMID:
21242525
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS.

Blood. 2010 Mar 11;115(10):1949-57. doi: 10.1182/blood-2009-08-238543. Epub 2010 Jan 11.

PMID:
20065291
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected].

de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J.

J Immunol. 2011 Feb 1;186(3):1503-11. doi: 10.4049/jimmunol.1001022. Epub 2010 Dec 27. Erratum in: J Immunol. 2011 Jun 15;186(12):7272.

PMID:
21187449
[PubMed - indexed for MEDLINE]
Free Article
10.

Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Simmons DP, Canaday DH, Liu Y, Li Q, Huang A, Boom WH, Harding CV.

J Immunol. 2010 Aug 15;185(4):2405-15. doi: 10.4049/jimmunol.0904005. Epub 2010 Jul 21.

PMID:
20660347
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.

Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.

J Immunother. 2007 Nov-Dec;30(8):789-97.

PMID:
18049330
[PubMed - indexed for MEDLINE]
12.

Type I interferon dependence of plasmacytoid dendritic cell activation and migration.

Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G.

J Exp Med. 2005 Apr 4;201(7):1157-67. Epub 2005 Mar 28.

PMID:
15795237
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II.

Benitez-Ribas D, Tacken P, Punt CJ, de Vries IJ, Figdor CG.

J Immunol. 2008 Oct 15;181(8):5219-24.

PMID:
18832675
[PubMed - indexed for MEDLINE]
Free Article
14.

Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.

Eur J Immunol. 2002 Nov;32(11):3235-45.

PMID:
12555669
[PubMed - indexed for MEDLINE]
15.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.

PMID:
21613613
[PubMed - indexed for MEDLINE]
Free Article
16.

Burn injury triggered dysfunction in dendritic cell response to TLR9 activation and resulted in skewed T cell functions.

Shen H, de Almeida PE, Kang KH, Yao P, Chan CW.

PLoS One. 2012;7(11):e50238. doi: 10.1371/journal.pone.0050238. Epub 2012 Nov 26.

PMID:
23189191
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Antitumor activity mediated by CpG: the route of administration is critical.

Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2011 Apr;34(3):279-88. doi: 10.1097/CJI.0b013e31820d2a05.

PMID:
21389870
[PubMed - indexed for MEDLINE]
18.

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation.

Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, Lee KD, Coffman RL, Barrat FJ.

J Exp Med. 2006 Aug 7;203(8):1999-2008. Epub 2006 Jul 24.

PMID:
16864658
[PubMed - indexed for MEDLINE]
Free PMC Article
19.
20.

Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells.

Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, Busch DH, Wagner H.

J Immunol. 2003 Mar 15;170(6):2802-5.

PMID:
12626528
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk